Stockscreener 앱 받기
1,200.06
1.14%
-13.85
시간 외 거래:
1204.94
4.88
+0.41%
전일 마감가:
$1,213.91
열려 있는:
$1208
하루 거래량:
2.34M
Relative Volume:
0.72
시가총액:
$1.07T
수익:
$72.25B
순이익/손실:
$25.28B
주가수익비율:
43.20
EPS:
27.781
순현금흐름:
$10.37B
1주 성능:
-2.43%
1개월 성능:
+6.07%
6개월 성능:
+12.78%
1년 성능:
+53.72%
1일 변동 폭
$1,183.34
$1,213.79
1주일 범위
$1,173.93
$1,232.00
52주 변동 폭
$623.78
$1,238.00
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,200.06 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
259.33 | 611.36B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.76 | 444.60B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
126.78 | 317.37B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.49 | 299.04B | 54.66B | 13.58B | 16.05B | 7.0171 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-16 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 재확인 | BofA Securities | Buy |
| 2025-12-15 | 재확인 | Goldman | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-10 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 재확인 | BMO Capital Markets | Outperform |
| 2025-10-14 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Charles River Laboratories International (CRL) On Lilly TuneLab Deal And The Valuation Debate - simplywall.st
Eli Lilly (LLY) Faces China Trial Probe While Handing Verzenios Rights To Innovent - simplywall.st
Is Eli Lilly (LLY) One of Billionaire Cliff Asness’ Best Healthcare Stock Picks ? - Insider Monkey
Why Is Eli Lilly (NYSE:LLY) Obesity Pill In Focus? - Kalkine Media
Medicare Expands Access to GLP-1 Drugs, Boosting Eli Lilly (LLY) and Novo Nordisk (NVO) - GuruFocus
Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China - Benzinga
$100 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today - Benzinga
Eli Lilly & Co. highlights its role in innovative diabetes care - AD HOC NEWS
Mounjaro from Eli Lilly & Co.dual-action diabetes drug expands US reach - AD HOC NEWS
Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results - FXEmpire
Eli Lilly (LLY) and Novo Nordisk (NVO) to Benefit from New Medic - GuruFocus
Medicare opens access to GLP-1 weight-loss drugs (LLY:NYSE) - Seeking Alpha
$Eli Lilly and Co (LLY.US)$ break and retest. 1300+ might be understatement from me. - Moomoo
Hybio challenges Eli Lilly with FDA bid for tirzepatide generic - China Daily
Hanmi Receives $75 Million Upfront from Eli Lilly - Businesskorea
Korea Lilly names Komatsu Seiya CEO to accelerate innovation pushCHOSUNBIZ - Chosunbiz
Innovent and Lilly Expand China Oncology Partnership with Verzenios Commercialisation Agreement - BioPharma APAC
Lawmakers press Eli Lilly for China drug trials tied to military-linked hospitals - AOL.com
Pennsylvania invests millions to train workers for Eli Lilly facility opening in 2031 - PennLive.com
Lilly taps Abbisko for $1.9B discovery deal - BioWorld News
Why is Eli Lilly stock sliding today? - Investing.com
U.S. Stocks Move | Eli Lilly and Co (LLY.US) Drops Over 2% as Weight-Loss Drug Included in Medicare Reimbursement for the First Time - 富途牛牛
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters? - Yahoo Finance
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness - Benzinga
Eli Lilly Transfers Commercialization Rights for Breast Cancer Drug in ChinaU.S. News - U.S. News - Money
Eli Lilly transfers commercialization rights for breast cancer drug in China - Reuters
Eli Lilly Upgraded, Carvana Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Eli Lilly (LLY) Stock Hits $1,230 in June 2026 — Strong Sales of Mounjaro & Zepbound Drive Gains - FXLeaders
Eli Lilly And Company (NYSE:LLY) Advances Metabolic Medicine Frontier - Kalkine Media
The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk - STAT
Ranking Wall Street's Trillion-Dollar Stocks From Most to Least Attractive, Based on Future Cash Flow - The Motley Fool
5 Reasons Eli Lilly Is a Better Stock to Buy Right Now Than SpaceX - The Motley Fool
Eli Lilly Is Dominating the GLP-1 Market: Here's What a $5,000 Investment Could Look Like in 5 Years - The Motley Fool
Lilly hands Innovent China rights to breast cancer drug Verzenios - Stock Titan
LLYLilly(Eli) & Co Latest SEC Filings - Finviz
Eli Lilly (LLY) Joins FDA PreCheck Pilot Program to Enhance Drug Manufacturing - GuruFocus
Eli Lilly (LLY) Joins FDA Pilot Program to Strengthen U.S. Drug Manufacturing - GuruFocus
Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters
Eli Lilly (LLY) Joins FDA PreCheck Pilot Program for Manufacturi - GuruFocus
Lilly, Regeneron selected for US program to review new manufacturing facilities faster, CNBC reports - Yahoo
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities - CNBC
How Is Eli Lilly (NYSE:LLY) Positioned As Healthcare Hits Record Highs? - Kalkine Media
Lilly partners with P2U on private Mounjaro dispensing service - Pharmacy Magazine
The Investment Case for Eli Lilly and Co (LLY): How Financial Gr - GuruFocus
U.S. Stock Market Update | Eli Lilly and Co (LLY.US) hits a new all-time high, up over 14% year-to-date - 富途牛牛
Here's Why Shares of Eli Lilly Hit an All-Time High on Friday - The Globe and Mail
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,350 - 富途牛牛
Lilly (LLY) Moves 7.1% Higher: Will This Strength Last? - Yahoo Finance
Lilly launches home delivery service for privately prescribed medicines - The Pharmacist News
ZAWYA: Lilly and Department of Health – Abu Dhabi aim to advance management of obesity and alzheimer’s disease - TradingView
Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher? - Insider Monkey
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
일라이 릴리 주식 (LLY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab |
Jun 10 '26 |
Sale |
1,150.77 |
2,500 |
2,876,925 |
29,804 |
1.41%
자본화:
|
볼륨(24시간):